Cubist expands hospital sales force
Executive Summary
Cubist will begin increasing its anti-infective acute care U.S. sales force from 99 to 135 reps immediately, the firm announced Nov. 22. The expansion follows a Nov. 21 decision by FDA to grant priority review to the company's sNDA for Cubicin in treatment of endocarditis and bacteremia caused by Staphylococcus aureus (1"The Pink Sheet" March 7, 2005, p. 39). The sales realignment, effective Jan. 1, will focus on increasing coverage for the broadened indication...
You may also be interested in...
Cubist Boosts Cubicin Sales Reps, Will Detail 80% Of Vancomycin Prescribers
Cubist will increase its Cubicin (daptomycin) sales force by one third in the first quarter, bringing the total to 100 reps, CEO Michael Bonney said
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.